Neupro (Rotigotine) Patent Expiration, LOE Window & CMS Spending

Neupro (Rotigotine) by Ucb: FDA Orange Book LOE 2032-03-01, 0 AB generics, $94.5M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUcb
FDA Application & PathwayN021829 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-03-01
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$94.5M
2024 Medicare Part D Spend$90.1M
2024 Medicaid Spend$4.5M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 18.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.